OT Partners with Hoomano to Securely Connect Robots and Deploy a Wide Range of Innovative Use Cases
OT (Oberthur Technologies), a leading global provider of embedded security software products and services, today announces its partnership with Hoomano, a pioneer in social robotics, focused on real-world interaction robotic software, to deploy new services in a secure environment for the Internet-of-Things and the Robotics space.
Through this partnership, OT and Hoomano bring together their expertise to develop robot-agnostic software solutions in a secured hardware environment. Hoomano already enhances social robots with artificial intelligence, so that the general public and robots can interact instinctively. With OT’s solution, robots will not only interact in the best possible way, they will also benefit from an optimized connectivity and essential level of trust to answer requirements of industries such as Retail, Banking, Hospitality & Healthcare.
At the INNOROBO event, OT and Hoomano will showcase customized and seamless user experience through a plethora of services emerging thanks to robotics: easy and automatic train subscription renewal to avoid queuing at counters and customized user experience in shops and banks for example.
“Thanks to this partnership we will bring secured connectivity solutions for the Internet-of-Things and Social robots. OT’s ambition is to enable robot or device manufacturers not only to connect their objects, but also to deploy customized services in a trusted way.”, said Marc Bertin Chief Technology Officer at OT.
“Connectivity and security are key enablers to deploy the most engaging, instinctive interactions and build mutual trust with our customers.” said Xavier Basset, Founder & CEO at Hoomano.
BlackBox for Robotics on Youtube : https://www.youtube.com/watch?v=MSqbRuUs6LY
Come and discover secured and interactive services for robotics at The INNOROBO event, in Paris, France, May 16-18 on Hoomano’s booth #Q10 Dock Pullman.
ABOUT OBERTHUR TECHNOLOGIES
OT
is a world leader in embedded digital security that protects you when
you connect, authenticate or pay.
OT is strategically positioned in high growth markets and offers embedded security software solutions for “end-point” devices as well as associated remote management solutions to a huge portfolio of international clients, including banks and financial institutions, mobile operators and governments, as well as manufacturers of connected objects and equipment.
OT employs over 6,500 employees worldwide, including almost 700 R&D people. With a global footprint of 4 regional secure manufacturing hubs and 39 secure service centers, OT’s international network serves clients in 169 countries. For more information : www.oberthur.com
DOWNLOAD THE
M WORLD,
All you need to know about the latest trends of the
Mobility world, available on AppStore and Google Play
www.oberthur.com/themworld
ABOUT HOOMANO
Hoomano is a pioneer in social robotics, focused on real-world
interaction robots software. Hoomano design, develops and deploys
software for social robots like Pepper and Nao (Softbank Robotics),
Buddy (Blue Frog Robotics), Heasy (Hease Robotics), and Cozmo (Anki).
Since 2014, their customers in retail, banking, transportation and
healthcare are using every day social robots “powered by Hoomano”. The
R&D team is focused on enhancing interactions with artificial
intelligence. Hoomano has its headquarter in Lyon, France and an office
in Tokyo, Japan.
For more information: www.hoomano.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005463/en/
Contact information
MEDIA CONTACT
Elan-Edelman
Chloé
Tisseuil, Tél. : +33 1 86 21 50 54
chloe.tisseuil@elanedelman.com
or
Hoomano
MEDIA
CONTACT
Tél. : +33 825 950 800
press@hoomano.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom